MFMartin Fussenegger

Martin Fussenegger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Martin Fussenegger has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Wilfried Weber

    INM – Leibniz Institute for New Materials Saarbrücken Germany

    15 shared publications
  • Nils Link

    Institute for Chemical and Bioengineering, ETH Zurich, Wolfgang‐Pauli‐Strasse 10, HCI F115, CH‐8093 Zurich, Switzerland; telephone: +41 44 633 34 48; fax: +41 44 633 12 34

    5 shared publications
  • Cornelia C. Weber

    Institute for Biomedical Engineering, Swiss Federal Institute of Technology, ETH Zurich, CH‐8044 Zurich, Switzerland

    4 shared publications
  • Marie Daoud-El Baba

    Institute for Chemical and Bioengineering, ETH Zurich, Wolfgang-Pauli-Strasse 10, HCI F115, CH-8093 Zurich, Switzerland and Institut Universitaire de Technologie, IUTA, Département Génie Biologique, F-69622 Villeurbanne Cedex, France

    4 shared publications
  • Shizuka Hartenbach

    Institute for Chemical and Bioengineering, ETH Zurich, Wolfgang-Pauli-Strasse 10, HCI F115, CH-8093 Zurich, Switzerland

    4 shared publications
  • Bettina Keller

    Institute of Chemical‐ and Bio‐Engineering, Swiss Federal Institute of Technology, ETH Hoenggerberg HCI F115, Wolfgang‐Pauli‐Strasse 10, CH‐8093 Zurich, Switzerland

    3 shared publications

Latest Publications

  • Functional cross‐kingdom conservation of mammalian and moss (Physcomitrella patens) transcription, translation and secretion machineries

    by Marc Gitzinger, Juliana Parsons, Ralf Reski, Martin Fussenegger

    Summary: Plants and mammals are separated by a huge evolutionary distance. Consequently, biotechnology and genetics have traditionally been divided into ‘green’ and ‘red’. Here, we provide comprehensive evidence that key components of the mammalian transcription, translation and secretion machineries are functional in the model plant Physcomitrella patens. Cross‐kingdom compatibility of different expression modalities originally designed for mammalian cells, such as native and synthetic promoters and polyadenylation sites, viral and cellular internal ribosome entry sites, secretion signal peptides and secreted product proteins, and synthetic transactivators and transrepressors, was established. This mammalian expression portfolio enabled constitutive, conditional and autoregulated expression of different product genes in a multicistronic expression format, optionally adjusted by various trigger molecules, such as butyrolactones, macrolide antibiotics and ethanol. Capitalizing on a cross‐kingdom‐compatible expression platform, we pioneered a prototype biopharmaceutical manufacturing scenario using microencapsulated transgenic P. patens protoplasts cultivated in a Wave Bioreactor. Vascular endothelial growth factor 121 (VEGF121) titres matched those typically achieved by standard protonema populations grown in stirred‐tank bioreactors. The full compatibility of mammalian expression systems in P. patens further promotes the use of moss as a cost‐effective alternative for the manufacture of complex biopharmaceuticals, and as a valuable host system to advance synthetic biology in plants.


  • Tricalcium phosphate nanoparticles enable rapid purification, increase transduction kinetics, and modify the tropism of mammalian viruses

    by Imke A.J. Dreesen, Norman A. Lüchinger, Wendelin J. Stark, Martin Fussenegger

    Adenoviral, adeno‐associated viral, and retroviral particles are chosen as gene delivery shuttles in more than 50% of all gene therapy clinical trials. Bulk availability of clinical‐grade viral particles and their efficiency to transduce the therapeutic cargo into specific target cells remain the most critical bottlenecks in gene therapy applications to date. Capitalizing on the flame‐spray technology for the reproducible economic large‐scale production of amorphous tricalcium phosphate nanoparticulate powders (ATCP), we designed a scalable ready‐to‐use gravity‐flow column set‐up for the straightforward concentration and purification of transgenic adenoviral, adeno‐associated viral, and lentiviral particles. Specific elution buffers enabled rapid release of viral particles from the ATCP matrix of the column and provided high‐titer virus preparations in an unsurpassed period of time. The interaction of ATCP with adenoviral, adeno‐associated viral, and lentiviral particles in solution increased the transduction kinetics of several mammalian cell lines in culture. The nanoparticles were also able to modify the tropism of murine leukemia virus (MLV) towards transduction of human cells. Based on these findings, we believe that the use of flame‐spray tricalcium phosphate nanoparticles will lead to important progress in the development of future gene therapy initiatives. Biotechnol. Bioeng. 2009;102: 1197–1208.


  • Molecular engineering of exocytic vesicle traffic enhances the productivity of Chinese hamster ovary cells

    by Ren‐Wang Peng, Martin Fussenegger

    A complex vesicle trafficking system manages the precise and regulated distribution of proteins, membranes and other molecular cargo between cellular compartments as well as the secretion of (heterologous) proteins in mammalian cells. Sec1/Munc18 (SM) proteins are key components of the system by regulating membrane fusion. However, it is not clear how SM proteins contribute to the overall exocytosis. Here, functional analysis of the SM protein Sly1 and Munc18c suggested a united, positive impact upon SNARE‐based fusion of ER‐to‐Golgi‐ and Golgi‐to‐plasma membrane‐addressed exocytic vesicles and increased the secretory capacity of different therapeutic proteins in Chinese hamster ovary cells up to 40 pg/cell/day. Sly1‐ and Munc18c‐based vesicle traffic engineering cooperated with Xbp‐1‐mediated ER/Golgi organelle engineering. Our study supports a model for united function of SM proteins in stimulating vesicle trafficking machinery and provides a generic secretion engineering strategy to improve biopharmaceutical manufacturing of important protein therapeutics. Biotechnol. Bioeng. 2009;102: 1170‐1181.


  • Quorum-Sensing-Based Toolbox for Regulatable Transgene and siRNA Expression in Mammalian Cells

    by Wilfried Weber, Laetitia Malphettes, Matthias Rinderknecht, Ronald G. Schoenmakers, Manuela Spielmann, Bettina Keller, Petra Van de Wetering, Cornelia C. Weber, Martin Fussenegger

    Technologies for regulated expression of multiple transgenes in mammalian cells have gathered momentum for bioengineering, gene therapy, drug discovery, and gene-function analyses. Capitalizing on recently developed mammalian transgene modalities (QuoRex) derived from Streptomyces coelicolor, we have designed a flexible and highly compatible expression vector set that enables desired transgene/siRNA control in response to the nontoxic butyrolactone SCB1. The construction-kit-like expression portfolio includes (i) multicistronic (pTRIDENT), (ii) autoregulated, (iii) bidirectional (pBiRex), (iv) oncoretro- and lentiviral transduction, and (v) RNA polymerase II-based siRNA transcription-fine-tuning vectors for straightforward implementation of QuoRex-controlled (trans)gene modulation in mammalian cells.


  • Open Access

    Intronically encoded siRNAs improve dynamic range of mammalian gene regulation systems and toggle switch

    by David Greber, Marie Daoud El-Baba, Martin Fussenegger

    Applications of conditional gene expression, whether for therapeutic or basic research purposes, are increasingly requiring mammalian gene control systems that exhibit far tighter control properties. While numerous approaches have been used to improve the widely used Tet-regulatory system, many applications, particularly with respect to the engineering of synthetic gene networks, will require a broader range of tightly performing gene control systems. Here, a generically applicable approach is described that utilizes intronically encoded siRNA on the relevant transregulator construct, and siRNA sequence-specific tags on the reporter construct, to minimize basal gene activity in the off-state of a range of common gene control systems. To demonstrate tight control of residual expression the approach was successfully used to conditionally express the toxic proteins RipDD and Linamarase. The intronic siRNA concept was also extended to create a new generation of compact, single-vector, autoinducible siRNA vectors. Finally, using improved regulation systems a mammalian epigenetic toggle switch was engineered that exhibited superior in vitro and in vivo induction characteristics in mice compared to the equivalent non-intronic system.


  • RepTAGs: Universal tags for isolation and labeling of proteins, for labeling live mammalian cells and for drug discovery

    by Wilfried Weber, Nils Link, Dominique Aubel, Cornelia C. Weber, Martin Fussenegger

    Methods for specific immobilization, isolation and labeling of proteins are central to the elucidation of cellular functions. Based on bacterial repressor proteins, which bind to specific target sequences in response to small molecules (macrolide and tetracycline antibiotics) or environmental parameters (temperature), we have developed a set of protein tags (RepTAGs), which enable reversible immobilization of the protein of interest on a solid support for the isolation and quantification as well as for the specific labeling of target proteins with fluorescent dyes for tracking them within a complex protein mixture. Similarly, live mammalian cells were specifically labeled with a fluorescent operator sequence bound to RepTAGs, which were directed towards the cell surface for easy discrimination between transfected and untransfected cell populations. Based on the drug-responsive RepTAG-DNA interactions, it was also possible to quantify or discover antibiotics in environmental samples or compound libraries by means of rapid, sensitive detection methods involving fluorescence polarization and bioluminescence. We believe that the universally applicable RepTAGs will become essential for the analysis and manipulation of proteins in the most diverse areas of protein chemistry and cell biology.

  • Open Access

    Adeno-associated viral vectors engineered for macrolide-adjustable transgene expression In mammalian cells and mice

    by David A Fluri, Marie Daoud-El Baba, Martin Fussenegger

    Background: Adjustable gene expression is crucial in a number of applications such as de- or transdifferentiation of cell phenotypes, tissue engineering, various production processes as well as gene-therapy initiatives. Viral vectors, based on the Adeno-Associated Virus (AAV) type 2, have emerged as one of the most promising types of vectors for therapeutic applications due to excellent transduction efficiencies of a broad variety of dividing and mitotically inert cell types and due to their unique safety features. Results: We designed recombinant adeno-associated virus (rAAV) vectors for the regulated expression of transgenes in different configurations. We integrated the macrolide-responsive E.REX systems (EON and EOFF) into rAAV backbones and investigated the delivery and expression of intracellular as well as secreted transgenes for binary set-ups and for self- and auto-regulated one-vector configurations. Extensive quantitative analysis of an array of vectors revealed a high level of adjustability as well as tight transgene regulation with low levels of leaky expression, both crucial for therapeutical applications. We tested the performance of the different vectors in selected biotechnologically and therapeutically relevant cell types (CHO-K1, HT-1080, NHDF, MCF-7). Moreover, we investigated key characteristics of the systems, such as reversibility and adjustability to the regulating agent, to determine promising candidates for in vivo studies. To validate the functionality of delivery and regulation we performed in vivo studies by injecting particles, coding for compact self-regulated expression units, into mice and adjusting transgene expression. Conclusion: Capitalizing on established safety features and a track record of high transduction efficiencies of mammalian cells, adeno- associated virus type 2 were successfully engineered to provide new powerful tools for macrolide-adjustable transgene expression in mammalian cells as well as in mice.


  • Open Access

    An engineered L-arginine sensor of Chlamydia pneumoniae enables arginine-adjustable transcription control in mammalian cells and mice

    by Shizuka Hartenbach, Marie Daoud-El Baba, Wilfried Weber, Martin Fussenegger

    For optimal compatibility with biopharmaceutical manufacturing and gene therapy, heterologous transgene control systems must be responsive to side-effect-free physiologic inducer molecules. The arginine-inducible interaction of the ArgR repressor and the ArgR-specific ARG box, which synchronize arginine import and synthesis in the intracellular human pathogen Chlamydia pneumoniae , was engineered for arginine-regulated transgene (ART) expression in mammalian cells. A synthetic arginine-responsive transactivator (ARG), consisting of ArgR fused to the Herpes simplex VP16 transactivation domain, reversibly adjusted transgene transcription of chimeric ARG box-containing mammalian minimal promoters (P ART ) in an arginine-inducible manner. Arginine-controlled transgene expression showed rapid induction kinetics in a variety of mammalian cell lines and was adjustable and reversible at concentrations which were compatible with host cell physiology. ART variants containing different transactivation domains, variable spacing between ARG box and minimal promoter and several tandem ARG boxes showed modified regulation performance tailored for specific expression scenarios and cell types. Mice implanted with microencapsulated cells engineered for ART-inducible expression of the human placental secreted alkaline phosphatase (SEAP) exhibited adjustable serum phosphatase levels after treatment with different arginine doses. Using a physiologic inducer, such as the amino acid l -arginine, to control heterologous transgenes in a seamless manner which is devoid of noticeable metabolic interference will foster novel opportunities for precise expression dosing in future gene therapy scenarios as well as the manufacturing of difficult-to-produce protein pharmaceuticals.